Drug intelligence / Profile preview

Tezobell

Development stage: Unknown
Lead developer: CKD OTTO Pharma
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

Tezobell is an oncology drug containing bortezomib, a proteasome inhibitor used for the treatment of multiple myeloma. It was developed by CKD OTTO Pharmaceuticals, a joint venture between South Korea's Chong Kun Dang Pharm Corp and Indonesia's PT Otto Pharmaceutical Industries. The drug is specifically indicated for patients with multiple myeloma who have received at least one prior therapy and have shown disease progression on their last therapy. It is supplied as a lyophilized powder in 1 mg and 3.5 mg vials for reconstitution and administration. Notably, Tezobell is produced in Indonesia's first halal-certified oncology manufacturing facility.

Brand names: Tezobell
Other names: bortezomib

Targets

26S proteasome

Beyond the preview

Go deeper on Tezobell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tezobell.

Explore the full profile